Biogen's Alzheimer’s drug fails to meet mid-stage trial goal
14/05/2026 12:02
May 14 (Reuters) - Biogen BIIB.O said on Thursday its Alzheimer’s drug did not meet the main goal of a mid-stage trial. (Reporting by Kamal Choudhury in Bengaluru; Editing by Jonathan Ananda) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout